Uflex Ltd Q3 FY2024 Concall Summary

Key Takeaways

• Packaging films in India are a loss-making industry: Management stated plainly that "everybody is operating at a loss" at the PAT level, a trend now in its second consecutive quarter, driven by severe oversupply.
• Overseas operations are the profit engine: Out of Rs. 426 crores in consolidated EBITDA, overseas business generated Rs. 255 crores, buoyed by robust demand and high utilization in the Americas.
• Backward integration is the margin recovery thesis: Trial runs have begun for the Panipat PET chips plant, with completion targeted by March. This, plus an Egypt plant later in FY25, is the primary lever to improve packaging film margins.
• Aseptic packaging is a bright spot for growth: Capacity is expanding from 700 crore to 1,200 crore packs per annum, set to come online before the next season, contributing to additional growth.
• What to watch next quarter: Whether the Red Sea disruption provides a tangible margin tailwind for local plants, the pace of European demand recovery, and the commercial start of the Panipat PET chips plant.

Packaging Films: A Margin Crisis in India

• Loss-making industry: In India, the packaging films sector is operating at a loss at the PAT level, with players at best marginally EBITDA positive. This distress has persisted for two quarters, with BOPET slightly more distressed than BOPP.
• Oversupply root cause: A bunching of capacity additions coincided with tepid consumer demand from the Russia-Ukraine war and US interest rate hikes, creating a demand-supply mismatch that management expects will take "a couple of years" to resolve.
• Spread compression: Contribution spreads have fallen from roughly Rs. 1 lakh/ton to Rs. 90,000/ton. When raw material prices fall, selling prices fall in tandem, so the benefit is passed to customers rather than retained as margin.
• Normalized margin target: Current consolidated EBITDA margin is ~12.5%, versus a normal range of 14.5–15%. The 3% gap must be corrected by improved European sentiment, better domestic demand-supply equilibrium, and captive PET chips usage.

Bhatia: "In India, in the packaging films, currently everybody is operating at a loss. And that has been the trend for the last 2 quarters and maybe marginally at an EBITDA positive, but overall, I don't think so there is anybody who is making any money at PAT level in the packaging films."

Regional Dynamics: Americas Strong, Europe Weak

• Americas at full throttle: The US plant achieved 100% capacity utilization this quarter, and the Mexico plant hit 92%. Management confirmed that "America markets are back" with robust demand.
• Europe continues to drag: Packaging films volume in Europe de-grew YoY, weighed down by the Russia-Ukraine war's impact on energy costs and higher interest rates dampening consumer demand.
• Red Sea disruption as a potential tailwind: The late-November Red Sea crisis has increased freight costs, insurance, and voyage times for exports into Europe. Management sees a parallel to COVID-era supply chain disruptions, where local plants like Uflex's benefited from a shift to local sourcing.
• Nigeria and Egypt FX sensitivity: Nigeria suffered a currency devaluation this quarter, and both Egypt and Nigeria remain sensitive areas, with central bank devaluations every 3 to 6 months creating balance sheet reinstatement losses.

Bhatia: "I think the local plants like ours with the Red Sea crisis will do better as we did better in the COVID times when we have seen the supply chain disruptions."

Backward Integration: The PET Chips Margin Lever

• Panipat plant imminent: Trial runs for the PET chips plant in India have started. The facility will produce chips for BOPET films and has a provision for bottle-grade chips, with full operations expected by March.
• Egypt plant to follow: A second PET chips backward integration facility in Egypt is slated for completion between Q2 and Q3 of FY25, adding reliability and pricing benefits to raw material availability.
• Cost savings timeline: Management expects cost savings to materialize from Q1 or Q2 after commercialization, as costs take 1–2 quarters to normalize post-commissioning.
• Strategic rationale: The backward integration is intended to culminate in better margins for the packaging films business overall by reducing reliance on external raw material pricing.

Aseptic Packaging & Other Growth Levers

• Aseptic capacity surge: Expansion from 700 crore to 1,200 crore packs per annum is underway. The bottlenecking completion will hit the market before the next season, which starts in January, contributing to additional growth.
• Other segments performing: Flexible packaging, aseptic packaging, holographic films, and other substrates like chemicals and adhesives all did well this quarter, maintaining profitability despite broader pricing pressure.
• Mexico volume doubles: Production volume in Mexico was up almost double YoY, alongside volume growth in Dubai and India, partially offsetting European weakness.
• Nigeria utilization outlook: Management is targeting 75–80% utilization for the time being, with a potential rise to 80–85% if export opportunities to the Americas materialize from Nigeria.

PCR Business: A Premium Play on Hold

• Strategy is premium, not substitution: The prime motive for PCR plants was to make value-added, PCR-grade PET films sold at a premium to virgin raw material, not to replace virgin raw material.
• Margin compression from virgin price collapse: When virgin raw material prices were high, margins on buying and converting old PET bottles were strong. As virgin prices fell drastically, the margin differential shrunk, and the PCR film market in Europe and America went into a tailspin.
• Egypt as a bright spot: The Egypt PCR facility sources bottles locally, avoiding import parity pricing and FX issues, so the differential margin remains available there.
• Demand recovery thesis: Management expects PCR film demand to recover over time as companies become more conscious about recycled content, with Europe and America leading the way.

Bhatia: "The prime motive was not to replace it with the virgin raw material. The prime motive was to make a value-added film with this and sell that film at a premium to the virgin raw material. It will happen over time, which will happen."

Balance Sheet & Capital Allocation

• Debt peak in FY25: Net debt is expected to peak at no more than Rs. 5,500 crores, with some projects commissioning in Q3 of FY25.
• Repayment from operations: Debt will be serviced through cash generation from normal business operations, with annual amortizations paid down. New CAPEX plans will be market-dependent and communicated to the market when made.
• FY24 CAPEX disclosed: After an initial deflection, management confirmed FY24 CAPEX at Rs. 1,004 crores. FY25 growth CAPEX is pegged at roughly \$100 million, plus maintenance CAPEX of Rs. 140–150 crores.
• Cautiously optimistic tone: Management expressed cautious optimism for a sharper recovery in the next few quarters, but declined to make firm statements on Europe until observing the next two quarters.

Bhatia: "I have been saying that there are amortizations which we keep on paying and then there are new plans for the CAPEX, which are made depending on the markets. So, whatever is the amortization annually, the debt will be paid to those levels only. And as and when there are new investment plans, we will obviously inform the market."

Guidance & Commitments

Key Metrics